Related Experiment Videos
Human plasma derived hepatitis B vaccine: Kenyan experience
F A Okoth1, P M Kaiguri, J Tuei
1Centre for Virus Research, KEMRI, Nairobi.
Insights
Hepaccine B vaccination demonstrated high efficacy in a study of 107 participants, with 97% developing protective antibodies. The vaccine was well-tolerated, showing minimal side effects like injection site soreness and headache.
Area of Science:
- Hepatitis B research
- Vaccinology
- Immunology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Effective vaccination strategies are crucial for preventing HBV transmission and its chronic sequelae.
- Assessing vaccine efficacy and safety in diverse populations is essential for public health initiatives.
Purpose of the Study:
- To evaluate the immunogenicity and safety profile of Hepaccine B.
- To determine the proportion of vaccinees achieving protective antibody levels against Hepatitis B surface antigen (anti-HBs).
Main Methods:
- A cohort of 107 individuals (aged 0-10 years and 10+ years) received Hepaccine B vaccination.
- Antibody levels (anti-HBs) were measured one month after the third vaccine dose.
- Participants were recruited from Kenya Medical Research Institute (KEMRI) staff and their families in Nairobi.
Main Results:
- A high seroconversion rate was observed, with 97% of vaccinees developing anti-HBs antibodies.
- The vaccine elicited a robust immune response, indicating efficacy in generating protective immunity.
- Reported side effects were infrequent and mild, primarily consisting of local soreness at the injection site and headache.
Conclusions:
- Hepaccine B is an effective vaccine, demonstrating a strong capacity to induce protective immune responses against Hepatitis B.
- The vaccine exhibits a favorable safety profile with minimal adverse events, making it a potentially valuable tool for Hepatitis B prevention.
- The findings support the use of Hepaccine B in vaccination programs aimed at controlling Hepatitis B transmission.
Objective:
To determine the efficacy and safety of hepaccine B.
Design:
Vaccination on first-come-first-served basis.
Setting:
Kenya Medical Research Institute (KEMRI) staff and families at Nairobi, Kenya.
Participants:
A total of 107 vaccinees aged 0-10 years and 10 years and above.
Main Outcome:
Antibody to hepatitis B surface antigen (anti HBs) checked one month after the third dose of the vaccine.
Results:
Ninety seven per cent of the vaccinees developed antiHBs. Side effects were few in the form of soreness at site of injection and headache.
Conclusion:
Hepaccine B produced good immune response in vaccinees with minimal side effects.